First Time Loading...
R

ReNeuron Group PLC
LSE:RENE

Watchlist Manager
ReNeuron Group PLC
LSE:RENE
Watchlist
Price: 3.375 GBX -2.17% Market Closed
Updated: May 8, 2024
Section:
 

Wall Street
Price Targets

RENE Price Targets Summary
ReNeuron Group PLC

Wall Street analysts forecast RENE stock price to drop over the next 12 months.

According to Wall Street analysts, the average 1-year price target for RENE is 2.907 GBX with a low forecast of 2.879 GBX and a high forecast of 2.993 GBX.

RENE Lowest Forecast
Wall Street Target
2.879 GBX
15% Downside
RENE Average Forecast
Wall Street Target
2.907 GBX
14% Downside
RENE Highest Forecast
Wall Street Target
2.993 GBX
11% Downside
Lowest
Price Target
2.879 GBX
15% Downside
Average
Price Target
2.907 GBX
14% Downside
Highest
Price Target
2.993 GBX
11% Downside
ReNeuron Group PLC Competitors:
Price Targets
TLX
Telix Pharmaceuticals Ltd
4% Upside
G
GNFT
Genfit SA
183% Upside
ALERS
Eurobio Scientific SA
110% Upside
HOOK
HOOKIPA Pharma Inc
434% Upside
TLX
Telix Pharmaceuticals Ltd
4% Upside
G
GNFT
Genfit SA
183% Upside
ALERS
Eurobio Scientific SA
110% Upside
HOOK
HOOKIPA Pharma Inc
434% Upside
300294
China Resources Boya Bio pharmaceutical Group Co Ltd
8% Upside
GRTS
Gritstone bio Inc
422% Upside
Z
ZURA
Zura Bio Ltd
290% Upside
APLT
Applied Therapeutics Inc
145% Upside

Revenue
Forecast

Revenue Estimate
ReNeuron Group PLC

For the last 8 years the compound annual growth rate for ReNeuron Group PLC's revenue is 43%. The projected CAGR for the next 2 years is 380%.

43%
Past Growth
380%
Estimated Growth
Estimates Accuracy
-62%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
ReNeuron Group PLC

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-8%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
ReNeuron Group PLC

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-54%
Average Miss
What are analyst estimates?

See Also

Summary
RENE intrinsic value, competitors valuation, and company profile.
DCF Valuation
RENE stock valuation using Discount Cash Flow valuation method.
Relative Valuation
RENE stock valuation using valuation multiples.
Wall Street Estimates
RENE price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
RENE stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is RENE's stock price target?
Price Target
2.907 GBX

According to Wall Street analysts, the average 1-year price target for RENE is 2.907 GBX with a low forecast of 2.879 GBX and a high forecast of 2.993 GBX.

What is ReNeuron Group PLC's Revenue forecast?
Projected CAGR
380%

For the last 8 years the compound annual growth rate for ReNeuron Group PLC's revenue is 43%. The projected CAGR for the next 2 years is 380%.

ALPHA SPREAD
Join more than 135,400+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.